AbbVie on
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Your search returned 1000 results
-
June 02, 2021- In SELECT-PsA 2, 29 percent of bDMARD-IR patients treated with continuous RINVOQ (upadacitinib, 15 mg, once daily) achieved minimal disease activity at 56 weeks, which was consistent with improvements from baseline seen at week 24[1],[2]
-
June 02, 2021- Long-term data from the Phase 3 SELECT-COMPARE trial show that continuous treatment with RINVOQ (upadacitinib, 15 mg, once-daily) plus MTX maintained rates of clinical remission and low disease activity through three years in adults with rheumatoid arthritis[1]
-
May 26, 2021-- Phase 3 ADVANCE trial results on the safety and efficacy of atogepant in the preventive treatment of migraine are among several abstracts
-
May 25, 2021-- VENCLYXTO® (venetoclax) in combination with a hypomethylating agent is a new regimen approved by the European Commission (EC) for patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy [1]
-
May 25, 2021- First presentation of three-year data from Phase 3 SELECT-COMPARE study assessing long-term efficacy and safety of RINVOQ® (upadacitinib) versus HUMIRA® (adalimumab) in patients with rheumatoid arthritis (RA)
-
May 24, 2021- In the ADVANCE trial, risankizumab (SKYRIZI) met co-primary endpoints of clinical remission and endoscopic response compared to placebo at 12 weeks in patients with intolerance or inadequate response to conventional and/or biologic therapy[1]
-
May 19, 2021-- 43 abstracts on six investigational and approved medicines across 12 cancer types to be presented at both meetings
-
May 10, 2021-- Acquisition adds Rapid Acoustic Pulse technology platform for improvement in appearance of cellulite in the buttocks and thighs --
-
April 30, 2021- Reports First-Quarter Diluted EPS of $1.99 on a GAAP Basis; Adjusted Diluted EPS of $2.95
-
April 27, 2021- New analyses of Phase 3 ARTEMIS studies provide further insights on duration and biodegradation of DURYSTA™ (bimatoprost intracameral implant)
-
April 23, 2021- Positive opinion based on data from the VIALE-A and M14-358 trials, which evaluated the safety, efficacy and pharmacokinetics of VENCLYXTO in combination with hypomethylating agents in adult patients with AML
-
April 07, 2021- Submissions supported by two Phase 3 studies in patients with active psoriatic arthritis in which SKYRIZI demonstrated improved skin and joint symptoms and physical function, with a greater proportion of patients achieving minimal disease activity versus placebo[1]
-
April 07, 2021-- Phase 3 ADVANCE trial results on the safety and efficacy of atogepant in the preventive treatment of migraine to be presented at the Clinical Trials Plenary Session; study was also only headache topic to earn Merit of Distinction in 2021
-
April 01, 2021Revolutionary, Clinically Proven Product Addresses Multi-Factorial Causes & Symptoms of Neck Aging
-
April 01, 2021- In SELECT-PsA 1, RINVOQ™ (upadacitinib, 15 mg and 30 mg) improved key joint and skin symptoms up to 24 weeks, including enthesitis[1]
-
March 31, 2021
-
March 30, 2021- If approved, atogepant will be the first and only oral CGRP receptor antagonist specifically developed for the preventive treatment of migraine[1]
-
February 25, 2021- If approved, this is expected to be the first eye drop to treat presbyopia
-
February 24, 2021- HUMIRA (adalimumab) is the first and only subcutaneous biologic treatment option for pediatric patients from 5 years of age with moderately to severely active ulcerative colitis[1]
Who we are
 |
Get to know the passionate people who make up AbbVie and the difference we strive to make, one patient at a time. Learn more
Sustainability
 |
Our commitment to science is a commitment to better our society. Read our 2025 ESG report
Key Facts
 |
Get a closer look at our impact.
Learn more
Annual report
 |
See our latest 2025 Annual Report on Form 10-K. Learn more
